New Methods Against Antibiotic Resistance

Antibiotic resistance is a global health crisis arising from various defense mechanisms bacteria develop against antibiotics. Bacteria can acquire resistance through structural changes that prevent antibiotic entry, efflux pumps that expel the drug, or enzymes that degrade the antibiotic. These mechanisms are not intentional but result from genetic mutations and natural selection. Frequent and improper use of antibiotics increases the survival and reproduction of resistant bacteria, exacerbating the problem. Therefore, antibiotic resistance is considered a threat beyond individual treatment, affecting public health worldwide.

Antimicrobial peptides (AMPs) are molecules found in the natural defense systems of many organisms, acting quickly against bacteria. AMPs can damage bacterial membranes or disrupt vital processes, offering a broad spectrum of activity. However, for clinical use, they must resist rapid degradation in the body, reach target sites effectively, and avoid harming healthy cells. Researchers are modifying the molecular structure of AMPs to make them more stable, safe, and effective. Additionally, new delivery methods are being developed to transport these molecules to infection sites.

Bacteriophages are viruses that infect bacteria, targeting specific strains while preserving beneficial microbiota. They show promise especially against multidrug-resistant infections. Challenges include selecting the right phage for each infection, ensuring treatment safety, and the potential for bacteria to develop phage resistance. Thus, bacteriophages are seen not as a standalone replacement for antibiotics but as a powerful tool in combating resistant infections.

The CRISPR-Cas system is a molecular tool that can cut specific DNA sequences, offering an innovative approach against antibiotic resistance. This technology can target and disable resistance genes in bacteria. However, for therapeutic use, safe and efficient delivery of genetic material to target bacteria, prevention of off-target effects, and clinical validation are required. While not yet a ready treatment, CRISPR-Cas represents a promising research area for future antimicrobial strategies.

Nanotechnology-based approaches can enhance the delivery of antibiotics to target sites, improving treatment efficacy. Nanoparticles made of silver, gold, or polymers can be designed to prolong drug retention at infection sites and achieve effectiveness at lower doses. These systems are particularly promising for treating biofilm-associated infections. However, safety, potential accumulation in the body, toxicity, and production costs must be carefully evaluated. Nanotechnology should be viewed as a complementary approach that strengthens existing treatments rather than a standalone solution.